PPICO Slides

Sample deck

A complete deck, built from one abstract

Fictional trial, real structure: ten slides covering the question, design, baseline, intervention and outcomes, with the charts drawn from the reported numbers. Move through it with the arrows, and export it in any format.

1 / 12
Journal club

High-flow nasal oxygen in acute hypoxemic respiratory failure

The HiFlo-ICU randomized trial

Marchetti R et al. N Engl J Med. 2024;391:1123-1134PICO slides

Use the arrow keys to move through the deck.

Journal club

High-flow nasal oxygen in acute hypoxemic respiratory failure

The HiFlo-ICU randomized trial

Marchetti R et al. N Engl J Med. 2024;391:1123-1134PICO slides
1
PICOS

The question in five parts

PPopulation

Adults admitted to an ICU with acute hypoxemic respiratory failure (PaO2/FiO2 < 300) who did not need immediate intubation

IIntervention

High-flow nasal oxygen at 50 L/min, FiO2 titrated to SpO2 92-96%, continued until weaning criteria met

CComparison

Conventional oxygen by non-rebreather mask at 15 L/min with the same SpO2 target

OOutcome

Primary: intubation within 28 days. Secondary: ICU length of stay, 90-day mortality, patient comfort

SStudy design

Multicenter (12 ICUs), open-label randomized controlled trial, 1:1 allocation with concealed assignment, blinded outcome adjudication, intention-to-treat analysis

Primary outcome
Intubation within 28 days

Absolute risk reduction 12.0% (95% CI 4.1 to 19.9), p = 0.03; NNT 9

Marchetti R et al. N Engl J Med. 2024;391:1123-1134PICO slides
2
Objective

What the trial set out to answer

  • Whether early high-flow nasal oxygen reduces the need for endotracheal intubation compared with conventional oxygen therapy
  • Hypothesis: HFNO lowers intubation by improving alveolar recruitment and reducing work of breathing
  • Secondary aim: compare ICU length of stay, mortality and patient-reported comfort
Marchetti R et al. N Engl J Med. 2024;391:1123-1134PICO slides
3
Methodology

Multicenter, open-label, randomized controlled trial

RCT12 ICUsn = 612Intention-to-treat
  • Adults randomized 1:1 within 6 hours of ICU admission using a central web-based system with permuted blocks
  • Allocation concealed; outcome adjudicators blinded to treatment arm
  • Primary endpoint: intubation within 28 days, adjudicated by two independent clinicians
  • Powered for a 12% absolute reduction in intubation (80% power, two-sided alpha 0.05)
Marchetti R et al. N Engl J Med. 2024;391:1123-1134PICO slides
4
Methodology

Patient disposition

Assessed for eligibilityn = 1,412
Randomisedn = 612
High-flow nasal oxygenn = 306
  • Lost to follow-up n = 3
  • Analysed n = 303
Conventional oxygenn = 306
  • Lost to follow-up n = 5
  • Analysed n = 301
Marchetti R et al. N Engl J Med. 2024;391:1123-1134PICO slides
5
Baseline

Groups were well balanced at enrollment

CharacteristicHFNO (n = 306)Conventional O2 (n = 306)
Age, years (mean ± SD)64 ± 1365 ± 12
Male sex58%61%
APACHE II (mean ± SD)21 ± 622 ± 6
PaO2/FiO2 ratio187 ± 53190 ± 48
Vasopressors at baseline24%22%
Pneumonia as cause63%60%

No clinically meaningful difference between arms

Marchetti R et al. N Engl J Med. 2024;391:1123-1134PICO slides
6
Intervention

How high-flow nasal oxygen was delivered

  • Flow started at 50 L/min and adjusted between 40 and 60 L/min for comfort
  • FiO2 titrated to SpO2 92-96%, weaned by 5 L/min every 4 hours once stable
  • Protocolized escalation: intubation if FiO2 > 0.9, respiratory rate > 35, or pH < 7.30
  • Nurses recorded device tolerance and comfort (0-10 scale) every 4 hours
Marchetti R et al. N Engl J Med. 2024;391:1123-1134PICO slides
7
Outcomes

Fewer intubations, shorter ICU stay

Primary and key secondary outcomes
0.68
Hazard ratio for intubation

Intubation HR 0.68 (95% CI 0.52 to 0.89), p = 0.005

Marchetti R et al. N Engl J Med. 2024;391:1123-1134PICO slides
8
Outcomes

Oxygenation improved faster with HFNO

PaO2/FiO2 ratio over 72 hours

Mean difference at 24 h: 54 mmHg (95% CI 38 to 70), p < 0.001

Marchetti R et al. N Engl J Med. 2024;391:1123-1134PICO slides
9
Takeaway

What this means for the ward tonight

  • HFNO reduced intubation by 12 percentage points: one intubation avoided for every 9 patients treated
  • Benefit was consistent across pneumonia and non-pneumonia subgroups
  • Mortality signal favored HFNO but the trial was not powered for mortality
  • Reasonable first-line support in hypoxemic failure when intubation is not yet indicated
Marchetti R et al. N Engl J Med. 2024;391:1123-1134PICO slides
10
Limitations

Read these results with care

  • Open-label design: clinicians knew the arm, which may influence the intubation decision
  • Single primary endpoint; secondary outcomes are exploratory and unadjusted
  • Excluded patients with hypercapnia, so findings do not extend to COPD exacerbation
  • Industry funding for device provision; authors report no control over analysis
Marchetti R et al. N Engl J Med. 2024;391:1123-1134PICO slides
11
Conclusion

Start high-flow oxygen early in hypoxemic failure

Early HFNO cut intubation by 12 points and improved oxygenation within 24 hours in adults with acute hypoxemic respiratory failure.

  • One intubation was avoided for every 9 patients treated with HFNO instead of conventional oxygen.
  • Mortality did not differ, so the decision rests on avoiding intubation and its complications.
Marchetti R et al. N Engl J Med. 2024;391:1123-1134PICO slides
12

Ready for your own paper?

Paste a PubMed link or upload the poster and get the same structure in under a minute.